Alendronate in the treatment of Paget's disease of bone

Bone

Volumn 20, Issue 3, 1997, Pages 263-271

  Khan, S A ^a   Vasikaran, S ^a   McCloskey, E V ^a   Beneton M N C ^a   Rogers, S ^a   Coulton, L ^a   Orgee, J ^a   Coombes, G ^a   Kanis, J A ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Alendronate; Bone turnover; Paget's disease of bone

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; HYDROXYPROLINE; OSTEOCALCIN;

ABDOMINAL PAIN; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE BIOPSY; BONE MINERALIZATION; BONE TURNOVER; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSPEPSIA; ENZYME ACTIVITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYDROXYPROLINE URINE LEVEL; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; ORAL DRUG ADMINISTRATION; PAGET BONE DISEASE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

AGED; ALENDRONATE; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BIOPSY; CALCIUM; FEMALE; HUMANS; HYDROXYPROLINE; MALE; OSTEITIS DEFORMANS;

EID: 0030899963     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(96)00364-X     Document Type: Article

References (42)

1. Adami, S., Salvagno, G., Guarrera, G., Montesanti, F., Garavelli, S., Rosini, S., and LoCascio, V. Treatment of Paget's disease of bone with intravenous 4-amino-1-hydroxybutlylidene-1, 1-bisphosphonate. Calcif Tissue Int 39:226-229; 1986.
2. Adami, S., Bhalla, A. K., Dorizzi, R., Montesanti, F., Rosini, S., Salvagno, G., and LoCascio, V. The acute phase response after bisphosphonate administration. Calcif Tissue Int 41:326-331; 1987.
3. Adamson, B. B., Gallacher, S. J., Byars, J., Ralston, S. H., Boyle, I. T., and Boyce, F. Mineralisation defects with pamidronate therapy for Paget's disease. Lancet 342:1459-1460; 1994.
4. Atkins, R. M., Yates, A. P. J., Gray, R. E. S., Urwin, G. H., Hamdy, N. A. T., Beneton, M. N. C., Rosini, S., and Kanis, J. A. Aminohexane diphosphonate in the treatment of Paget's disease of bone. J Bone Miner Res 2:273-279; 1987.
5. Attardo-Parrinello, G., Merlini, G., Pavesi, F., Crema, F., Fiorentini, M. L., and Ascari, E. Effects of a new aminodiphosphonate (aminohydroxybutilidene diphosphonate) in patients with osteolytic lesions from metastases and myelomatosis. Comparison with dichloromethylene diphosphonate. Arch Int Med 147:1629-1633; 1987.
6. Bickerstaft, D. R., O'Doherty, D. P., McCloskey, E. V., Hamdy, N. A. T., Mian, M., and Kanis, J. A. Effects of amino-butylidene disphosphonate in hypercalcaemia due to malignancy. Bone 12:17-20; 1991.
7. Boyce, B. F., Smith, L., Fogelman, I., Johnson, E., Ralston, S., and Boyle, I. T. Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. Lancet 1:821-824; 1984.
8. Boyce, B. F. Uses and limitations of bone biopsy in management of metabolic bone disease. In: Clinical endocrinology and metabolism. London: Balliere and Tindall; 1988.
9. Canfield, R., Rosner, W., Skinner, J., McWhorter, J., Resnick, L., Feldman, F., Kammerman, S., Ryan, K., Kunigonis, M., and Bohne, W. Diphosphonate therapy of Paget's disease of bone. J Clin Endocrinol Metab 44:96-106: 1977.
10. Chapuy, M. C., Charon, S. A., and Meunier, P. J. Sustained biochemical effects of short treatment of Paget's disease of bone with dichloro-methylene diphosphonate. Metab Bone Dis Rel Res 4:325-328: 1983.
11. Devlin, R. A., Retallack, R. W., Fenton, A. J., Grill, V., Gutteridge, D. H., Kent, G. N., Prince, R. L., and Worth, G. K. Long-term elevation of 1.25-dihydroxyvitamin D after short-term intravenous administration of pamidronate in Paget's disease of bone. J Bone Miner Res 9:81-85: 1994.
12. Eyres, K. S., Marshall, P., McCloskey, E. V., Douglas, D. L., and Kanis J. A. Spontaneous fractures in a patient treated with low doses of etidronic acid (disodium etidronate). Drug Safety 7:162-165; 1992.
13. Fleisch, H. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemia and metastatic bone disease. Drugs 42:919-944; 1991.
14. Fouldes, J., Shih, M. E., and Parfitt, A. M. Frequency distributions of tetracycline-based measurements: Implications for the interpretation of bone formation indices in the absence of double-labeled surfaces. J Bone Miner Res 5:1063-1067; 1990.
15. Gertz, B., Kline, W. F., Matuszewski, B. K., Sacco, J. F., Lasseter, K. C., and Porras, A. G. Oral bioavailability and dose proportionality of alendronate in postmenopausal women. J Bone Miner Res 6(Suppl. 1):281; 1991.
16. Gibbs, C. J., Aaron, J. E., and Peacock, M. Osteomalacia in Paget's disease treated with short term, high dose etidronate. BMJ 292:1227-1229; 1986.
17. Gray, R. E. S., Yates, A. J. P., Preston, C. J., Smith, R., Russell, R. G. G., and Kanis, J. A. Duration of effects of oral diphosphonate therapy in Paget's disease of bone. Q J Med 245:755-767; 1987.
18. Harinck, H. I. J., Papapoulos, S. E., Blanksma, H. J., Moolenaar, A. J., Vermeiji, P., and Bijvoet, O. L. M. Paget's disease of bone: Early and late responses to three different modes of treatment with aminohydroxyproplidene bisphosphonate (APD). BMJ 295:1301-1305; 1987.
19. Kanis, J. A. and Gray, R. E. Long-term follow-up observations on treatment in Paget's disease of bone. Clin Orthop Rel Res 217:99-125; 1987.
20. Kanis, J. A., Gertz, B. J., Singer, F., and Ortolani, S. Rationale for the use of alendronate in osteoporosis. Osteopor Int 5:1-13; 1995.
21. Kanis, J. A. and Yates, A. J. P. Measuring serum calcium. BMJ 290:728-729; 1985.
22. Kanis, J. A. Monitoring the treatment of Paget's disease with etidronate. Calcif Tissue Int 36:629-631; 1984.
23. Kanis, J. A. Pathophysiology and treatment of Paget's disease of the bone. London: Dunitz; 1991.
24. Khairi, M. R. A., Altman, R. D., DeRosa, G. P., Zimmerman, J., Schenk, R. K., and Johnston, C. C. Sodium etidronate in the treatment of Paget's disease of bone. Ann Intern Med 87:656-663; 1977.
25. Kozak, S., Rizzoli, R., Treschel, U., and Fleisch, H. Effect of two bisphosphonates on the hypercalcaemia and hypercalciuria induced by the Walker 256 carcinosarcoma in thyroparathyrodectomised rats. Cancer Res 47:6193-6197; 1987.
26. McCloskey, E. V., Yates, A. J. P., Beneton, M. N. C., Galloway, J., Harris, S., Kanis, J. A. Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man. Bone 8(Suppl. 1):35-41; 1987.
27. Nagant de Deuxchaisnes, C., Rombouts-Lindemans, C., Esselinckx, W., Devogelaer, J. P., Withofs, H., Meersseman, F., Malghem, J., and Maldague, B. Treatment of Paget's disease with the diphosphonate APD. A biological and radiological study. In: Diphosphonates and bone. Geneva: Editions Medicine et Hygiene; 1982; 303-327.
28. O'Doherty, D. P., Bickerstaff, D. R., McCloskey, E. V., Hamdy, N. A. T., Beneton, M. N. C., Harris, S., Mian, M., and Kanis, J. A. Treatment of Paget's disease of bone with aminohydroxy-butylidene bisphosphonate. J Bone Miner Res 5:483-191; 1990.
29. O'Doherty, D. P., Gertz, B. J., Tindale, W., Sciberras, D. G., Survill, T. T., and Kanis, J. A. Effects of five daily 1 hour infusions of alendronate in Paget's disease of bone. J Bone Miner Res 7:81-87; 1992.
30. O'Doherty, D. P., Bickerstaff, D. R., McCloskey, E. V., Eyres, K. S., and Kanis, J. A. Radiographic healing of osteolytic Paget's disease in the tibia with alendronate. J Orthop Rheumatol 4:153-157; 1991.
31. Papapoulos, S. E., Frolich, M., Mudde, A. H., Harinck, H. I. J., van den Berg, H., and Bijvoet, O. L. M. Serum osteocalcin in Paget's disease of bone: Basal concentration and response to bisphosphonate treatment. J Clin Endocrinol Metab 65:89-94; 1987.
32. Parfitt, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. A., Malluche, H., Meunier, P. J., Ott, S. M., and Recker, R. R. Bone histomorphometry: Standardization of nomenclature, symbols, and units. J Bone Miner Res 2:595-610; 1987.
33. Pedrazzoni, M., Palummeri, E., Ciotti, G., Davoli, L., Pioli, G., Girasole, G., and Passen, M. Short-terrn effects on bone and mineral metabolism of 4-amino-1-hydroxybutylidene-1, 1-disphosphonate (ABDP) in Paget's disease of bone. Bone Miner 7:301-307; 1989.
34. Price, P. A. and Baukol, S. A. 1.25 dihydroxyvitamin D increases serum levels of vitamin K-dependent bone protein. J Biol Chem 99:928-935; 1981.
35. Schenk, R., Eggli, P., Fleisch, H., and Rosini, S. Quantative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int 35:342-349; 1986.
36. Shinoda, H., Adamek, G., Felix, R., Fleisch, H., Schenk, R., and Hagan, P. Structure-activity relationships of various bisphosphonates. Calcif Tissue Int 35:87-99; 1983.
37. Stutzer, A., Fleisch, H., and Treschel, U. Short and long term effects of A single dose of bisphosphonate on retinoid-induced bone resorption in thyroparathy-roidectominised rats. Calcif Tissue Int 43:294-299; 1988.
38. Taube, T., Beneton, M. N. C., McCloskey, E. V., Rogers, S., Greaves, M., and Kanis, J. A. Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol 49:192-198; 1992.
39. Thompson, D. D., Seedor, J. G., Weinreb, M., Rosini, S., and Rodan, G. A. Aminohydroxybutane bisphosphonate inhibits bone loss due to immobilisation in rats. J Bone Miner Res 5:279-286; 1990.
40. Udenfriend, S. A specific method for the analysis of hydroxyproline in tissues and urine. Ann Biochem 228:347-349; 1960.
41. Yamamoto, M., Markatos, A., Seedor, J. G., Masarachia, P., Gentile, M., Rodan, G. A., and Balena, R. The effects of the aminobisphosphonate alendronate on thyroid hormone-induced osteopenia in rats. Calcif Tissue Int 53:278-282; 1993.
42. Yates, A. J. P., Gray, R. E. S., Urwin, G., Preston, C., Russell, R. G. G., Percival, R. C., Atkins, R. M., Hamdy, N. A. T., Beneton, M. N. C., and Kanis, J. A. Intravenous clodronate in the treatment and retreatment of Paget's disease of bone. Lancet 1:1474-1477; 1985.